(Tiper Stock Exchange) – Shedir Pharmaa group listed on Euronext Growth Milan and active in the field of nutraceuticals and pharmaceuticals, closed 2022 with consolidated revenues equal to 54.6 million euros (+20% compared to 31 December 2021), a EBITDA equal to approximately 11.3 million (+30% compared to 31 December 2021) and equal to 21% of consolidated revenues, a Net income of 5.9 million euros (+51% compared to 31 December 2021). There net financial position it has net cash and cash equivalents of 5.6 million euros (6.8 million compared to 31 December 2021).
“2022 was a very positive year – commented theTO Antonio Scala – The Group has demonstrated excellent ability to compete in a highly competitive sector both in Italy and abroad. Solid foundations have been laid so that we can continue on a solid and organic growth path”.
The Board of Directors resolved to propose to the Shareholders’ Meeting the distribution of a dividend gross ordinary amount of 0.17 euro per share. This distribution, if approved by the Shareholders’ Meeting, will take place starting from May 2, 2023, with record date May 3, 2023 and payment date May 4, 2023.